Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Emily Dorman

Showing results (1-10 of 7) with videos related to

Pageof 1
Sort By:
Expert Review of Pharmacoeconomics & Outcomes Research|November 29, 2012
Demand for male contraceptionEmily Dorman, David Bishai
Journal of Medical Economics|September 22, 2015
The budget impact of introducing delayed-release dimethyl fumarate for treatment of relapse-remitting multiple sclerosis in CanadaEmily Dorman, Anuraag R Kansal, Sujata Sarda
Journal of the International AIDS Society|November 14, 2014
Cost-effectiveness of DTG+ABC/3TC versus EFV/TDF/FTC for first-line treatment of HIV-1 in the United StatesSiyang Peng, Ali Tafazzoli, Emily Dorman, et al.
Journal of Medical Economics|May 3, 2015
Cost-effectiveness of DTG + ABC/3TC versus EFV/TDF/FTC for first-line treatment of HIV-1 in the United StatesSiyang Peng, Ali Tafazzoli, Emily Dorman, et al.
Journal of Comparative Effectiveness Research|December 7, 2017
Front-line treatment of patients with chronic lymphocytic leukemia: a systematic review and network meta-analysisYingxin Xu, Kyle Fahrbach, Emily Dorman, et al.
Clinical Therapeutics|January 8, 2017
Indirect Treatment Comparisons of Ibrutinib Versus Physician's Choice and Idelalisib Plus Ofatumumab in Patients With Previously Treated Chronic Lymphocytic LeukemiaSonja Sorensen, Mark Wildgust, Nishan Sengupta, et al.
Contraception|September 10, 2017
Modeling the impact of novel male contraceptive methods on reductions in unintended pregnancies in Nigeria, South Africa, and the United StatesEmily Dorman, Brian Perry, Chelsea B Polis, et al.
Pageof 1

Showing results (1-10 of 7) with videos related to

Sort By:
Pageof 1
Expert Review of Pharmacoeconomics & Outcomes Research|November 29, 2012
Demand for male contraceptionEmily Dorman, David Bishai
Journal of Medical Economics|September 22, 2015
The budget impact of introducing delayed-release dimethyl fumarate for treatment of relapse-remitting multiple sclerosis in CanadaEmily Dorman, Anuraag R Kansal, Sujata Sarda
Journal of the International AIDS Society|November 14, 2014
Cost-effectiveness of DTG+ABC/3TC versus EFV/TDF/FTC for first-line treatment of HIV-1 in the United StatesSiyang Peng, Ali Tafazzoli, Emily Dorman, et al.
Journal of Medical Economics|May 3, 2015
Cost-effectiveness of DTG + ABC/3TC versus EFV/TDF/FTC for first-line treatment of HIV-1 in the United StatesSiyang Peng, Ali Tafazzoli, Emily Dorman, et al.
Journal of Comparative Effectiveness Research|December 7, 2017
Front-line treatment of patients with chronic lymphocytic leukemia: a systematic review and network meta-analysisYingxin Xu, Kyle Fahrbach, Emily Dorman, et al.
Clinical Therapeutics|January 8, 2017
Indirect Treatment Comparisons of Ibrutinib Versus Physician's Choice and Idelalisib Plus Ofatumumab in Patients With Previously Treated Chronic Lymphocytic LeukemiaSonja Sorensen, Mark Wildgust, Nishan Sengupta, et al.
Contraception|September 10, 2017
Modeling the impact of novel male contraceptive methods on reductions in unintended pregnancies in Nigeria, South Africa, and the United StatesEmily Dorman, Brian Perry, Chelsea B Polis, et al.
Pageof 1